FLT3-ITD

[Clinical Cancer Research] The combination of crenolanib and sorafenib was tolerable with antileukemic activities and rare emergence of FLT3-TKD mutations, which warrants further investigation.

[Journal of Cancer Research and Clinical Oncology] Nox4 inactivation in normal HSCs and progenitor cells caused a minor reduction in HSC numbers and reconstitution capacity.

[Cancer Research] The authors established cells with acquired resistance to the allosteric SHP2 inhibitor SHP099 from two FLT3-ITD-positive AML cell lines.

[Bone Marrow Transplantation] Scientists investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance graft-versus-leukemia effects against FLT3 internal tandem duplication mutant transfected Ba/F3 leukemia in mice.

[Nature Communications] Researchers showed that pyruvate dehydrogenase kinase 1 (PDK1) acted as a targetable determinant of different metabolic states in AML.

[Blood Advances] Researchers provided insight into the relapsed or refractory (R/R) AML molecular profile and the impact of FLT3 inhibitors on mutational evolution associated with treatment resistance and benefit of gilteritinib across a wide spectrum of molecular and genetic subgroups in FLT3-mutated R/R AML.